Glucagon – the new ‘insulin’ in the pathophysiology of diabetes

  title={Glucagon – the new ‘insulin’ in the pathophysiology of diabetes},
  author={Leon S. Farhy and Anthony McCall},
  journal={Current Opinion in Clinical Nutrition and Metabolic Care},
  • L. Farhy, A. McCall
  • Published 1 July 2015
  • Medicine, Biology
  • Current Opinion in Clinical Nutrition and Metabolic Care
Purpose of reviewAutoimmune destruction of the &bgr; cells is considered the key abnormality in type 1 diabetes mellitus and insulin replacement the primary therapeutic strategy. However, a lack of insulin is accompanied by disturbances in glucagon release, which is excessive postprandially, but insufficient during hypoglycaemia. In addition, replacing insulin alone appears insufficient for adequate glucose control. This review focuses on the growing body of evidence that glucagon abnormalities… 
The New Biology and Pharmacology of Glucagon.
This review summarizes the extensive historical record and the more recent provocative direction that integrates the prominent role of glucagon in glucose elevation with its under-acknowledged effects on lipids, body weight, and vascular health that have implications for the pathophysiology of metabolic diseases, and the emergence of precision medicines to treat metabolic diseases.
Role of Glucagon in Automated Insulin Delivery.
Tripartite cell networks for glucose homeostasis
The hierarchical organization of tripartite cell networks, and recent biophysical modeling are introduced to systematically understand the oscillations and interactions of, , and cells in pancreatic islets.
Regulation of hepatic gluconeogenesis by nuclear factor Y transcription factor in mice
A previously unrecognized physiological function of NF-Y is revealed in controlling glucose metabolism by up-regulating the gluconeogenic genes Pck1 and G6pc and may offer an attractive therapeutic approach to manage type 2 diabetes.
Replacing Pumps with Light Controlled Insulin Delivery
  • S. Friedman
  • Biology, Medicine
    Current Diabetes Reports
  • 2019
The aim of this review is to summarize the development of the photoactivated depot (PAD) approach for the minimally invasive and continuously variable delivery of insulin by demonstrating that it can release native, bioactive insulin into diabetic animals in response to light signals from a small external LED light source.
A Primary Role in Glucose Homeostasis and Connection to Therapeutics: Beyond Glycemic Control is an Integral Part of Diabetes Etiology.
Poor maternal nutrition during gestation in sheep alters prenatal muscle growth and development in offspring.
It is found that poor maternal nutrition during gestation contributes to altered offspring muscle growth during early fetal development which persists throughout the fetal stage and is consistent with increased protein accretion, changes in muscle function and increased metabolic activity during myogenesis.
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
The historical pharmacological approaches to treat obesity and glucose intolerance are focused on and how the knowledge obtained by these studies led to the discovery of unimolecular polypharmacology is described.
A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development
A comprehensive overview of the quantitative approaches that have been reported since the 2008 review by Landersdorfer and Jusko in an increasing order of complexity, starting with glucose homeostasis models is provided.


Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.
It is concluded that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes, indicating that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.
It remains an ongoing task to identify the ideal routes and regimens of their delivery and potentially that of other hormones to restore the deficient and disordered hormonal environment of the pancreas to achieve a near normal metabolic state.
Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes
The present review contains a summary of established concepts as well as new information about the regulation of α-cells by glucose, amino acids, fatty acids and other nutrients, focusing especially on glucagon release, glucagon synthesis and α-cell survival.
Possible Contribution of Taurine to Distorted Glucagon Secretion in Intra-Islet Insulin Deficiency: A Metabolome Analysis Using a Novel α-Cell Model of Insulin-Deficient Diabetes
Results indicate that the metabolic alterations induced by IRKD in α-cells, especially the increase of taurine, may lead to the distorted glucagon response inIRKD cells, suggesting the importance of taurusine in the paradoxical glucagons response and the resultant glucose instability in insulin-deficient diabetes.
A review of artificial pancreas technologies with an emphasis on bi‐hormonal therapy
The attributes of glucagon and its use in bi‐hormonal systems are focused on, with a view to preventing and treating hypoglycaemia in patients with type 1 diabetes.
Dual‐hormone treatment with insulin and glucagon in patients with type 1 diabetes
This review proposes dual‐hormone treatment with insulin and glucagon as a method for achieving near normalization of blood glucose levels without increasing hypoglycaemia frequency and weight gain.
Glucagon regulates orexin A secretion in humans and rodents
Glucagon inhibits OXA secretion in humans and animals, irrespective of changes in glucose or insulin levels, and may influence energy expenditure, body weight, food intake and glucose metabolism.
Insulin and glucagon signaling in the central nervous system
The prevalence of the obesity and diabetes epidemic has triggered tremendous research investigating the role of the central nervous system (CNS) in the regulation of food intake, body weight gain and glucose homeostasis, suggesting a complementary action of the two hormones in regulating feeding behavior.
Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*
  • P. Cryer
  • Medicine, Biology
  • 2002
Perhaps the most compelling support for HAAF is the finding that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycaemia reverses hypoglyCAemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients.
Glucose regulation of glucagon secretion.